NCT04165330 2025-02-24
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
Sarcoma Oncology Research Center, LLC
Phase 1/2 Active not recruiting
Clinical Trials
5 trialsNCT05816499 2024-06-17
AK104IIT018
Shanghai Chest Hospital
Phase 1/2 Active not recruiting
NCT04507906 2022-06-28
Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC
Shanghai Chest Hospital
Phase 1/2 Completed
NCT04273815 2020-07-08
A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT03706287 2020-04-06
Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 1/2 Unknown